NCT00095225 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)


Sponsors: Genentech	Phases: Phase II
Indications	Acronym:
Non-Small-Cell Lung Carcinoma Neoplasm Recurrence, Local
Age Groups: Adult Senior	Gender: Both
Names: Drug: Avastin (bevacizumab) Drug: Tarceva (erlotinib HCl)	Enrollment: 122

Additional information about NCT00095225.